Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CTS (CTS)

CTS Corp. adds Kimberly MacKay to board, expanding it from seven to eight members

Neutral Impact 2 of 5 leadership Written later

CTS Corporation increased its board from seven to eight members and elected Kimberly MacKay to fill the new seat, effective November 5, 2025. MacKay is SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services, Inc., and will serve on the Nominating, Governance and Sustainability Committee and the Technology and Transactions Committee.

Key points

  • Board size increased from seven to eight members effective November 5, 2025
  • Kimberly MacKay is SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services, Inc.
  • MacKay will serve on the Nominating, Governance and Sustainability Committee and the Technology and Transactions Committee
  • The company will enter into an indemnification agreement with MacKay

The filing

CompanyCTS (CTS)
Form8-K, current report
Filed with the SECNov 6, 2025, 9:00 AM ET
Accession number0001193125-25-268239

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.